Logo
x

Search

Subscribe Now

fibrodysplasia ossificans progressiva

Ipsen Reports the Withdrawal of NDA for Palovarotene to Treat Fibrodysplasia Ossificans Progressiva

Ipsen Reports the Withdrawal of NDA for Palovarotene to Treat Fibrodysplasia Ossificans Progressiva

  • August 13, 2021
Ipsen Reports the US FDA's Acceptance of NDA for Palovarotene to Treat Fibrodysplasia Ossificans Progressiva

Ipsen Reports the US FDA's Acceptance of NDA for Palovarotene to Treat Fibrodysplasia Ossificans Progressiva

  • May 31, 2021
Regeneron Pauses Dosing of Garetosmab (REGN2477) in P-II LUMINA-1 Study for Fibrodysplasia Ossificans Progressiva

Regeneron Pauses Dosing of Garetosmab (REGN2477) in P-II LUMINA-1 Study for Fibrodysplasia Ossificans Progressiva

  • November 2, 2020
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.